(Q39407492)

English

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks

scientific article published on February 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks (English)

1 reference

Europe PubMed Central

11 September 2017

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

R Stark

1

1 reference

Europe PubMed Central

11 September 2017

C Dahlöf

2

1 reference

Europe PubMed Central

11 September 2017

S Haughie

3

1 reference

Europe PubMed Central

11 September 2017

J Hettiarachchi

4

1 reference

Europe PubMed Central

11 September 2017

Eletriptan Steering Committee

5

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

1 February 2002

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

22

1 reference

Europe PubMed Central

11 September 2017

1

1 reference

Europe PubMed Central

11 September 2017

23-32

1 reference

Europe PubMed Central

11 September 2017

Sumatriptan. An updated review of its use in migraine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Comparisons between a new drug and active and placebo controls in an efficacy clinical trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

An improved approximate formula for calculating sample sizes for comparing two binomial distributions

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Acute management of migraine: triptans and beyond

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2002.00300.X

21 January 2018

Identifiers

10.1046/J.1468-2982.2002.00300.X

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39407492&oldid=1826289487"